top of page

Insights and News Curated for Life Science Experts by Life Science Experts....
INSIGHTS HUB


Warren Buffett’s Hiring Rule: Why Integrity Comes First
Warren Buffett’s hiring philosophy has long been quoted in business circles, and for good reason. As he prepares to step down as CEO of...


Deepfakes: A Growing Threat to Hiring in the Life Sciences Industry
As Life Sciences recruiting becomes more selective and AI has continued advancement, incorporating these technologies into recruitment...


The FTC Ban on Non-Competes – From Life Science Recruiters’ Perspective
In a landmark decision, the Federal Trade Commission (FTC) has voted 3-2 to approve the issuance of a final rule that could reshape the...
Search
Medtronic to Acquire Contego Medical for $380M Plus Potential Additional Payments to Expand Vascular Treatment Portfolio
Galway, Ireland, November 16, 2026 (PR Newswire) -- Medtronic plc (NYSE: MDT) has announced its intent to acquire Contego Medical, Inc., a privately held medical device company specializing in technologies for carotid artery disease and peripheral thrombectomy, in a transaction valued at $380 million, with potential additional payments following the acquisition. The deal builds on Medtronic's existing relationship with Contego, including an exclusive U.S. distribution agree
GeneDx Appoints Everett Cunningham as CEO to Lead Next Phase of Genomic Diagnostics Growth
Gaithersburg, MD, November 18, 2026 (Business Wire) -- GeneDx Holdings Corp. (NASDAQ: WGS), a genomics company specializing in rare disease diagnosis and genomic testing, has appointed Everett Cunningham as Chief Executive Officer and a member of its Board of Directors, effective on or before December 15, 2026. Cunningham will succeed Katherine Stueland, who will step down as CEO and board member when he assumes the role and remain with the company as an advisor through Jan
Science Corporation Raises $400M in Series D Financing at $3.5B Valuation to Advance Vision-Restoring Implants and Brain-Computer Interface Technology
Alameda, CA, November 17, 2026 (Bloomberg) -- Science Corporation, a medical technology startup founded by former Neuralink president Max Hodak, has raised $400 million in a Series D financing round, bringing its reported valuation to $3.5 billion. Investors include Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech. The financing will support the expansion and commercialization of the company's PRIMA retinal implant, a d
Procyrion Appoints Jason Whiting as CEO Following Leadership Transition
Houston, TX, November 17, 2026 (PR Newswire) -- Procyrion, Inc., a medical device company developing innovative circulatory support technologies for patients with advanced heart failure, has appointed Jason Whiting as its new Chief Executive Officer. Whiting succeeds the company's outgoing leadership as Procyrion enters its next phase of development and commercialization. He brings extensive executive leadership experience in the medical device industry, including expertise
Eli Lilly to Acquire Calytrix Bio for Up to $1.5B to Expand Neuroscience Drug Pipeline
Indianapolis, IN, November 16, 2026 (Reuters) -- Eli Lilly and Company has agreed to acquire Calytrix Bio, a privately held biotechnology company developing treatments for neurological and neurodegenerative diseases, in a transaction valued at up to $1.5 billion. The deal includes an upfront payment and additional milestone-based payments tied to the achievement of specified development and commercial objectives. The acquisition is expected to strengthen Lilly's neuroscienc
Setara Biosciences Raises $90M in Series A Financing to Advance Precision Medicines for Rare Genetic Diseases
San Diego, CA, October 30, 2026 (Business Wire) -- Setara Biosciences, a biotechnology company focused on developing precision medicines for rare genetic diseases, has announced a $90 million Series A financing round to advance its drug development programs targeting rare genetic disorders and related expansion indications. The financing will support the company's research and development activities, including the advancement of its precision medicine pipeline, clinical dev
Anavex Life Sciences Appoints Terrie Kellmeyer, Ph.D., as Permanent President and CEO to Lead Clinical Development Strategy
New York, NY, November 3, 2026 (Yahoo Finance) -- Anavex Life Sciences Corp. (NASDAQ: AVXL), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (CNS) diseases, has appointed Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer, effective November 1, 2026. Kellmeyer, who previously served as the company's Interim CEO, will also join its Board of Directors. She brings more than 30 years of biopharmaceutical indu
Rockwell Medical to Acquire Vantive’s Global Hemodialysis Business for $125M in Contingent Payments
Wixom, MI, November 3, 2026 (Business Wire) -- Rockwell Medical, Inc. (NASDAQ: RMTI) has entered into a definitive agreement to acquire Vantive Limited’s in-center hemodialysis business across 35 jurisdictions, including the United States, for a base purchase price of $125 million, subject to customary adjustments. The transaction will be financed through two $50 million term loans and a $25 million convertible note provided by Vantive. Read full article here.
Align Technology Appoints Jennifer L. Davis as CEO, Succeeding Joseph Hogan Effective December 31, 2026
Tempe, AZ, October 28, 2026 (Business Wire) -- Align Technology, Inc. (NASDAQ: ALGN), a global medical device company specializing in digital orthodontics and restorative dentistry, has appointed Jennifer L. Davis as its next President and Chief Executive Officer, effective December 31, 2026. Davis will succeed Joseph M. Hogan, who has served as CEO since 2015 and will step down from the role at year-end before retiring from the Board of Directors in June 2027. Read full ar
Dren Bio Raises $350M in Private Financing to Advance Rare Blood Cancer Treatment Toward Commercialization
San Carlos, CA, October 29, 2026 (Business Wire) -- Dren Bio, a privately held, clinical-stage biotechnology company developing antibody-based therapies for cancer, autoimmune, and other serious diseases, has closed an oversubscribed $350 million private financing round co-led by Juvia Group and Lightspeed Venture Partners. The financing also includes participation from new investors Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management, and OrbiMed
Alaunos Therapeutics Acquires Velaris Therapeutics and Raises $350M to Advance Pulmonary Hypertension Pipeline
Fort Lauderdale, FL, October 13, 2026 (Alaunos) -- Alaunos Therapeutics, Inc. (NASDAQ: TCRT) has completed its acquisition of Velaris Therapeutics, Inc., a privately held biotechnology company developing therapies for pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases. The acquisition adds a pipeline of biologic drug candidates, including ActRII-Fc ligand traps and an anti-PDGF-B antibody, designed to target signaling imbalances that contribute to pu
AngioDynamics Appoints Eric Honroth as President and CEO Following Planned Leadership Transition
Latham, NY, October 8, 2026 (AngioDynamics) -- AngioDynamics, Inc. (NASDAQ: ANGO) has appointed Eric Honroth as President and Chief Executive Officer and a member of its Board of Directors, effective November 2, 2026. Honroth will succeed Jim Clemmer, who is retiring after ten years leading the medical technology company and will remain in a consulting role to support the transition. Honroth brings more than 20 years of leadership experience across the medical device and li
Stryker Invests $400M in CMR Surgical to Advance Robotic-Assisted Surgery
Portage, MI, and Cambridge, England, October 12, 2026 (Stryker) -- Stryker Corporation has announced a strategic alliance with CMR Surgical, a U.K.-based medical device company specializing in robotic-assisted surgery, through an approximately $400 million (£300 million) preferred equity investment to support innovation and global commercialization of CMR’s Versius surgical robotic portfolio. The agreement grants Stryker an exclusive option to acquire 100% of CMR Surgical’s
Harmony Biosciences Appoints Peter Anastasiou as CEO as Jeffrey Dayno Plans Retirement
Plymouth Meeting, PA, October 12, 2026 (Harmony Biosciences) -- Harmony Biosciences Holdings, Inc. has appointed Peter Anastasiou, its current Senior Executive Vice President and Chief Operating Officer and a former board member, as President and Chief Executive Officer, effective January 1, 2027. He will succeed Jeffrey M. Dayno, M.D., who will retire on December 31, 2026, after nine years with the company and serve as a non-executive advisor throughout 2027 to support the
STERIS to Acquire Xodus Medical for $2.1B to Expand Surgical Consumables Portfolio
Dublin, Ireland, October 12, 2026 (Steris) -- STERIS plc has signed a definitive agreement to acquire Xodus Medical, Inc., a Pennsylvania-based medical device company specializing in surgical products focused on patient and operating room staff safety, for $2.1 billion at closing. The transaction is expected to generate approximately $300 million in net present value cash tax benefits, bringing the effective net purchase price to approximately $1.8 billion, with additional
Anaconda Biomed Raises $56M to Advance Stroke Thrombectomy Platform
Barcelona, Spain and Marin, CA, September 23, 2026 (Globe Newswire) -- Anaconda Biomed has closed a $56 million financing round led by Omega Funds, with participation from new investor Spain’s Co-investment Fund (FOCO) and existing backers including Asabys, Ysios Capital and CDTI. The company will use the proceeds to advance its neurovascular device portfolio and complete the ongoing ATHENA pivotal IDE study evaluating its ANA Funnel Catheter in a randomized 327-patient tri
Travere Therapeutics Names Bradley Campbell as New CEO in Planned Leadership Transition
San Diego, CA, September 21, 2026 (Business Wire) -- Travere Therapeutics announced that Eric Dube, Ph.D., will step down as President and CEO in December after nearly eight years leading the company. Bradley L. Campbell, former President and CEO of Amicus Therapeutics, will succeed Dube effective December 1, 2026, and will also join Travere’s Board of Directors. Dube will remain with the company as an executive advisor through February 15, 2027, to support the leadership t
Axogen to Acquire BioCircuit Technologies for $200M to Expand Peripheral Nerve Repair Portfolio
Alachua and Tampa, FL, September 10, 2026 (Axogen) -- Axogen has entered into a definitive agreement to acquire privately held medical device company BioCircuit Technologies for $200 million in cash. The acquisition adds NerveTape, the first FDA-approved sutureless peripheral nerve repair device, to Axogen’s portfolio and is expected to broaden its addressable market. The transaction is expected to close in the fourth quarter of 2026, subject to customary conditions, includ
CereVasc Appoints Tony Kingsley as CEO Ahead of eShunt Commercial Launch
Boston, MA, September 15, 2026 (PR Newswire) -- CereVasc has appointed Tony Kingsley as President and Chief Executive Officer, effective September 15, succeeding Dan Levangie, who will transition to Chairman of the Board. Kingsley brings extensive commercial leadership experience in neurology and healthcare and will oversee the company’s strategy and operations as it prepares for the commercial introduction of its eShunt System. Levangie will continue supporting CereVasc’s
Electra Therapeutics Prices Upsized $350M IPO to Fund Late-Stage Drug Development
South San Francisco, CA, September 17, 2026 (Globe Newswire) -- Electra Therapeutics has priced an upsized initial public offering of 23.3 million shares at $15 per share, generating approximately $350 million in gross proceeds. The company also granted underwriters a 30-day option to purchase up to an additional 3.5 million shares, potentially increasing the proceeds from the offering. Electra plans to use the capital to advance its clinical-stage pipeline, led by ipsoprub
bottom of page

